Logo

ATOS

Atossa Therapeutics, Inc.

ATOS

Atossa Therapeutics, Inc. • NASDAQ
$0.78 ▼ -0.29% (-0.00)
Market Cap $100.43 M
52w High $1.31
52w Low $0.55
Dividend Yield 0%
P/E -3.38
Volume 184.27K
Outstanding Shares 129.17M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $9.247M ▲ $-8.692M ▼ 0% $-0.07 ▼ $-8.688M ▲
Q2-2025 $0 $9.04M ▲ $-8.423M ▼ 0% $-0.065 ▼ $-9.036M ▼
Q1-2025 $0 $7.414M ▲ $-6.718M ▼ 0% $-0.052 ▼ $-7.41M ▼
Q4-2024 $0 $7.147M ▲ $-6.347M ▲ 0% $-0.05 ▲ $-7.147M ▼
Q3-2024 $0 $6.385M $-7.23M 0% $-0.058 $-6.381M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $51.845M ▼ $58.012M ▼ $8.225M ▲ $49.787M ▼
Q2-2025 $57.857M ▼ $64.515M ▼ $6.82M ▲ $57.695M ▼
Q1-2025 $65.116M ▼ $70.747M ▼ $5.425M ▲ $65.322M ▼
Q4-2024 $71.084M ▼ $76.444M ▼ $4.967M ▼ $71.477M ▼
Q3-2024 $74.766M $79.477M $5.796M $73.681M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.692M ▼ $-6.005M ▲ $-7K ▼ $0 $-6.012M ▲ $-6.012M ▲
Q2-2025 $-8.423M ▼ $-7.259M ▼ $0 ▲ $0 $-7.259M ▼ $-7.259M ▼
Q1-2025 $-6.718M ▼ $-5.959M ▲ $-9K ▼ $0 ▼ $-5.968M ▼ $-5.968M ▲
Q4-2024 $-6.347M ▲ $-7.051M ▼ $0 ▲ $3.369M ▲ $-3.682M ▲ $-7.051M ▼
Q3-2024 $-7.23M $-4.75M $-10K $0 $-4.76M $-4.76M

Five-Year Company Overview

Income Statement

Income Statement Atossa is still a pure R&D story with essentially no product revenue yet. Expenses are driven by research, development, and corporate costs, which consistently produce losses each year. The losses have been relatively steady rather than sharply worsening, but the business is clearly not self-funding and depends on outside capital while its drug programs advance. Earnings per share have been negative throughout, reflecting this early-stage, development‑only profile.

Balance Sheet

Balance Sheet The balance sheet is simple and fairly clean. Assets are mostly cash, with little in the way of physical assets or inventory, which fits a clinical‑stage biotech. The company reports no financial debt, which reduces balance‑sheet risk and interest burden. Equity has been built mainly through issuing shares over time. Overall, it looks like a cash‑rich, debt‑free balance sheet, but one that must be continuously supported until a commercial product emerges.

Cash Flow

Cash Flow Cash is flowing out of the business to fund trials and operations, with negative operating cash flow in most years and no meaningful capital spending. This pattern is typical for a biotech in the clinical stage. The key question for investors is how long the existing cash can support the pipeline before additional funding is needed and on what terms any new capital would be raised, given the history of reverse splits and likely past dilution.

Competitive Edge

Competitive Edge Atossa operates in a highly competitive and well‑funded area of oncology, going up against large pharmaceutical companies and other biotechs working on breast cancer therapies. Its main asset, (Z)-endoxifen, is designed to improve on a widely used standard treatment, which gives it a clear clinical narrative but also puts it under intense comparative scrutiny. The company’s competitive strength rests largely on its patent portfolio, its specialized focus on certain breast cancer settings (such as pre‑surgery treatment and prevention in high‑risk women), and its ability to show clearly better outcomes or safety than existing options. Until later‑stage data are available, its competitive position is promising but unproven.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Atossa’s story. The company is trying to turn a well‑known breast cancer drug pathway into a more precise, more predictable therapy by delivering the active metabolite directly and protecting its most potent form. The enteric‑coated (Z)-endoxifen design, dual mechanism on estrogen receptors and signaling proteins, and a broad program spanning treatment, pre‑surgery use, and risk reduction all point to a focused but ambitious R&D strategy. Early and mid‑stage trial results in breast density reduction and tumor activity are encouraging signs, but they still need to be confirmed in larger, later‑stage studies. The exploratory work beyond breast cancer, such as potential use in Duchenne muscular dystrophy, adds long‑term optionality but is at a very early stage.

Summary

Atossa is a classic clinical‑stage biotech: no commercial revenue, recurring R&D‑driven losses, and a balance sheet dominated by cash with no debt. The investment case lives or dies on the success of its lead drug, (Z)-endoxifen, and the strength of its intellectual property around that molecule. The company appears to be financially conservative with a focus on preserving cash, but it will almost certainly need additional capital before reaching commercialization. The main opportunities lie in demonstrating clear clinical and safety advantages in breast cancer treatment and prevention, while the main risks center on trial outcomes, regulatory decisions, future dilution, and tough competition from established cancer drugs and other emerging therapies.

NEWS

November 17, 2025 · 9:07 AM UTC

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Read more

November 12, 2025 · 8:15 AM UTC

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Read more

November 6, 2025 · 8:00 AM UTC

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Read more

October 21, 2025 · 8:00 AM UTC

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Read more

October 15, 2025 · 8:00 AM UTC

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Read more